Other Events ·
Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket…
SYRESpyre Therapeutics, Inc.
Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072. Both low and high doses demonstrated statistically significant benefits compared to placebo on primary or secondary endpoints, including DAS28-CRP and ACR20/ACR50 responses at Week 12. The drug was well-tolerated with a safety profile consistent with the TL1A class. However, the magnitude of efficacy did not meet the company's internal bar to prioritize SPY072 as a monotherapy in RA. The results provide proof-of-mechanism for TL1A inhibition and support its potential in other autoimmune diseases and as a combination component. Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies.